Antibiotice
Știință și suflet

The distribution of the net profit for 2025, setting the gross dividend per share and establishing the payment date starting with October 28, 2026.

Antibiotice S.A. convenes shareholders to vote at the Ordinary General Meeting of Shareholders:

- *The approval of the distribution of the net profit for the financial year 2025 in a 50% quota, setting the gross dividend in the amount of 0.019877174 lei per share and establishing the payment date starting with 28.10.2026 - pursuant to Article 1 paragraph 1 letter f of Government Ordinance no. 64/2001 regarding the distribution of profit to national companies, national companies and commercial companies with full or majority state capital, as well as to autonomous public utilities.*

or

- *The approval of the distribution of the net profit for the financial year 2025 in a quota of 90%, setting the gross dividend in the amount of 0.035778913 lei per share and establishing the payment date* starting on 28.10.2026 pursuant to the Memorandum 626 553/ 16.04.2026 of the Ministry of Finance, approved in the government meeting of 16.04.2026.

GENERAL DIRECTOR
Mr. Ioan NANI

FINANCIAL DIRECTOR
Mrs. Paula COMAN

Annex no. 1

The distribution of the net profit for 2025, setting the gross dividend per share and establishing the payment term

The distribution of the net profit relating to the financial year 2025, reported based on the audited individual financial statements, is based on the following legal requirements:

- the G.O. no. 64/2001 regarding the distribution of profits to national companies and commercial companies with full or majority state capital, as well as to autonomous public administrations, with subsequent amendments and completions;
- the Law on Commercial Companies No. 31/1990, with subsequent amendments and supplements;
- the Law no. 227/2015 on the Fiscal Code, with subsequent amendments and supplements;
- the Law no. 24/2017 on the issuers of financial instruments and market operations;
- the Decision of the Ordinary General Meeting of Shareholders no. 1 of 28.03.2025, regarding the approval of the income and expenditure budget for 2025 of Antibiotice S.A.

The net profit of the 2025 financial year, reported based on the audited annual financial statements, is worth 51,769,472 lei, distributed according to legal requirements:

Destination	Value (lei)
- legal reserve, established at the maximum level from the profit of previous years	0
- other reserves for tax facilities	19,437,719
- the establishment of the company's own sources of financing for projects co-	
financed from external loans (Government Ordinance no. 64/2001 article 1,	5,643,147
paragraph 1, letter c1)	13,344,303
- dividends, of which:	7,074,786
dividends due to the majority shareholder	6,269,517
dividends due to other legal entities and individuals	13,344,303
- the company's own sources of financing	
Net profit for the year 2025, reported based on the audited annual financial statements	

- Other reserves in the amount of 19,437,719 lei represent tax facilities for the profit invested in technological equipment, electronic computers and peripheral equipment, ..., as well as in computer programs produced and/or purchased according to Article 22, paragraph 5 of Law no. 227/2015 on the Fiscal Code;

The amount of 13,344,303 lei from the net profit for the year 2025 is distributed as dividends proportional to the share of participation in the share capital as follows:

Ministry of Health (53.0172%)	7,074,786 lei
Other legal entities and individuals (46.9828%)	6,269,517 lei

The amount of 13,344,303 lei is the company's own source of financing according to the legal provisions.

The value of the gross dividend per share of 0.019877174 lei/share was calculated by corroborating the value of 13,344,303 lei of the dividends due to shareholders, according to the proposal for the distribution of the net result for the year 2025, with the number of shares of 671,338,040 components of the subscribed and paid-up share capital.

The payment of dividends for the year 2025 will be made starting with 28.10.2026, according to the legal provisions in force. We note that the dividend payment value is calculated by rounding to two decimal places.

The dividend tax will be calculated and withheld by Antibiotice S.A. in accordance with the requirements of Law no. 227/2015 on the Fiscal Code.

GENERAL DIRECTOR	**FINANCIAL DIRECTOR**
Mr. Ioan NANI	**Mr. Paula COMAN**

Annex no. 2

Distribution of net profit for 2025, setting the gross dividend per share and establishing the payment term

The distribution of the net profit relating to the financial year 2025, reported based on the audited individual financial statements, is based on the following legal requirements:

- the G.O. no. 64/2001 on the distribution of profits to national companies, national companies and commercial companies with full or majority state capital, as well as to autonomous public administrations, with subsequent amendments and completions;
- the Law on Commercial Companies No. 31/1990, with subsequent amendments and completions;
- the Law no. 227/2015 on the Fiscal Code, with subsequent amendments and supplements;
- the Law no. 24/2017 on the issuers of financial instruments and market operations;
- the Decision of the Ordinary General Meeting of Shareholders no. 1 of 28.03.2025, regarding the approval of the income and expenditure budget for 2025 of Antibiotice S.A.

The net profit of the 2025 financial year, reported based on the audited annual financial statements, is worth 51,769,472 lei, distributed according to legal requirements:

Destination	Value (lei)
- legal reserve, established at the maximum level from the profit of previous years	0
- other reserves for tax benefits	19,437,719
- establishing own sources of financing for projects co-financed from external loans (Government Ordinance no. 64/2001 art. 1, paragraph 1, letter c1)	5,643,147
- dividends, of which:	24,019,745
dividends due to the majority shareholder	12,734,614
dividends due to other legal entities and individuals	11,285,131
- the company's own sources of financing	2,668,861

The net profit for the year 2025, reported based on the audited annual financial statements

- Other reserves in the amount of 19,437,719 lei are tax facilities for the profit invested in technological equipment, electronic computers and peripheral equipment, ..., as well as in computer programs produced and/or purchased according to article 22, paragraph 5 of Law no. 227/2015 on the Fiscal Code;

The amount of 24,019,745 lei from the net profit for the year 2025 is distributed as dividends proportional to the share of participation in the share capital as follows:

Ministry of Health (53.0172%)	12,734,614 lei
Other legal entities and individuals (46.9828%)	11,285,131 lei

The amount of 2,668,861 lei represents the company's own source of financing according to the legal provisions.

The value of the gross dividend per share of 0.035778913 lei/share was calculated by corroborating the value of 24,019,745 lei of dividends due to shareholders, according to the proposal for the distribution of the net result for the year 2025, with the number of shares of 671,338,040 components of the subscribed and paid-up share capital.

The payment of dividends for the year 2025 will be made starting with 28.10.2026, according to the legal provisions in force. We note that the dividend payment value is calculated by rounding to two decimal places.

The dividend tax will be calculated and withheld by Antibiotice S.A. in accordance with the requirements of Law no. 227/2015 on the Fiscal Code.

GENERAL DIRECTOR — **FINANCIAL DIRECTOR**

Mr. Ioan NANI — **Mr. Paula COMAN**